CD133 expression in rectal cancer after preoperative chemoradiotherapy

Cancer Science

Volumn 101, Issue 4, 2010, Pages 906-912

  Kojima, Motohiro ^a   Ishii, Genichiro ^a   Atsumi, Naho ^a   Nishizawa, Yuji ^b   Saito, Norio ^b   Ochiai, Atsushi ^a  

^a Research Center for Innovative Oncology   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; FLUOROURACIL; HERMES ANTIGEN; KI 67 ANTIGEN; PROTEIN P53; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; TREATMENT OUTCOME; ADJUVANT THERAPY; AGED; COMPARATIVE STUDY; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; PATHOLOGY; RECTUM TUMOR;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD44; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PEPTIDES; PROGNOSIS; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957271302     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01478.x     Document Type: Article

References (42)

1. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3 (12): 895-902.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414 (6859): 105-11.
3. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006; 6 (6): 425-36.
4. Ishii H, Iwatsuki M, Ieta K et al. Cancer stem cells and chemoradiation resistance. Cancer Sci 2008; 99 (10): 1871-7.
5. Klonisch T, Wiechec E, Hombach-Klonisch S et al. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med 2008; 14 (10): 450-60.
6. Liu JM, Mao BY, Hong S, Liu YH, Wang XJ. The postoperative brain tumour stem cell (BTSC) niche and cancer recurrence. Adv Ther 2008; 25 (5): 389-98.
7. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3 (7): 730-7.
8. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445 (7123): 106-10.
9. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445 (7123): 111-5.
10. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104 (24): 10158-63.
11. Patrawala L, Calhoun T, Schneider-Broussard R et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25 (12): 1696-708.
12. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100 (7): 3983-8.
13. Tang DG, Patrawala L, Calhoun T et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007; 46 (1): 1-14.
14. Miraglia S, Godfrey W, Yin AH et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90 (12): 5013-21.
15. Yin AH, Miraglia S, Zanjani ED et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90 (12): 5002-12.
16. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001; 2 (2): 82-91.
17. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004; 95 (12): 930-5.
18. Dallas NA, Xia L, Fan F et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009; 69 (5): 1951-7.
19. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444 (7120): 756-60.
20. Sagar J, Chaib B, Sales K, Winslet M, Seifalian A. Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int 2007; 7: 9.
21. Smith LM, Nesterova A, Ryan MC et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008; 99 (1): 100-9.
22. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345 (9): 638-46.
23. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336 (14): 980-7.
24. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351 (17): 1731-40.
25. Glimelius B, Sorbye H, Balteskard L et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008; 19 (5): 909-14.
26. Sobin L, Wittekind C. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors, 6th edn. New York: John Wiley-Liss, Inc., 2002.
27. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12 (1): 19-23.
28. Wheeler JM, Warren BF, Jones AC, Mortensen NJ. Preoperative radiotherapy for rectal cancer: implications for surgeons, pathologists and radiologists. Br J Surg 1999; 86 (9): 1108-20.
29. Shia J, Guillem JG, Moore HG et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 2004; 28 (2): 215-23.
30. Rullier A, Laurent C, Vendrely V, Le Bail B, Bioulac-Sage P, Rullier E. Impact of colloid response on survival after preoperative radiotherapy in locally advanced rectal carcinoma. Am J Surg Pathol 2005; 29 (5): 602-6.
31. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73 (11): 2680-6.
32. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008; 99 (8): 1578-83.
33. Tran TA, Kallakury BV, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 1997; 28 (7): 809-14.
34. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008; 99 (8): 1285-9.
35. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008; 99 (4): 653-8.
36. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998; 292: 435-45.
37. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11 (1): 69-82.
38. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5 (9): 744-9.
39. Du L, Wang H, He L et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008; 14 (21): 6751-60.
40. Huh Jw, Kim HR, Kim YJ et al. Expression of standard CD44 in human colorectal carcinoma: association with prognosis. Pathol Int 2009; 59: 241-6.
41. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009; 27: 844-50.
42. Shimada Y, Ishii G, Nagai K et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci 2009; 100 (11): 2054-9.